Antonio Canosa

List of Publications by Year
in descending order

83 papers	2,951 citations	218677 26 h-index	197818 49 g-index
86 all docs	86 docs citations	86 times ranked	3534 citing authors

#	Article	IF	Citations
1	Amyotrophic lateral sclerosis caregiver burden and patientsâ€™ quality of life during COVID-19 pandemic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 146-148.	1.7	15
2	What is amyotrophic lateral sclerosis prevalence?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 203-208.	1.7	8
3	Italian adaptation of the Beaumont Behavioral Inventory (BBI): psychometric properties and clinical usability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 81-86.	1.7	10
4	Tailoring patientsâ€™ enrollment in ALS clinical trials: the effect of disease duration and vital capacity cutoffs. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 108-115.	1.7	1
5	Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2242-2250.	6.4	9
6	Effects of intracellular calcium accumulation on proteins encoded by the major genes underlying amyotrophic lateral sclerosis. Scientific Reports, 2022, 12, 395.	3.3	7
7	Causal associations of genetic factors with clinical progression in amyotrophic lateral sclerosis. Computer Methods and Programs in Biomedicine, 2022, 216, 106681.	4.7	3
8	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264.	12.4	38
9	The diagnostic value of the Italian version of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 527-531.	1.7	10
10	Brain¹⁸fluorodeoxyglucose-positron emission tomography changes in amyotrophic lateral sclerosis withTARDBPmutations. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1021-1023.	1.9	4
11	Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study. The Lancet Digital Health, 2022, 4, e359-e369.	12.3	19
12	Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 424-429.	1.7	2
13	Social cognition deficits in amyotrophic lateral sclerosis: A pilot crossâ€sectional populationâ€based study. European Journal of Neurology, 2022, 29, 2211-2219.	3.3	8
14	Respiratory support in a population-based ALS cohort: demographic, timing and survival determinants. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1024-1026.	1.9	8
15	Differential Neuropsychological Profile of Patients With Amyotrophic Lateral Sclerosis With and Without C9orf72 Mutation. Neurology, 2021, 96, e141-e152.	1.1	17
16	Brain metabolic changes across Kingâ€™s stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1124-1133.	6.4	10
17	Brain metabolic correlates of apathy in amyotrophic lateral sclerosis: An 18Fâ€FDGâ€positron emission tomography stud. European Journal of Neurology, 2021, 28, 745-753.	3.3	10
18	Metabolic brain changes across different levels of cognitive impairment in ALS: a¹⁸F-FDG-PET study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 357-363.	1.9	14

#	Article	IF	Citations
19	Neck flexor weakness at diagnosis predicts respiratory impairment in amyotrophic lateral sclerosis. European Journal of Neurology, 2021, 28, 1181-1187.	3.3	4
20	Mutational Analysis of Known ALS Genes in an Italian Population-Based Cohort. Neurology, 2021, 96, e600-e609.	1.1	23
21	The interplay among education, brain metabolism, and cognitive impairment suggests a role of cognitive reserve in Amyotrophic Lateral Sclerosis. Neurobiology of Aging, 2021, 98, 205-213.	3.1	15
22	Validation of the Italian version of self-administered ALSFRS-R scale. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 151-153.	1.7	9
23	Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 308-311.	1.7	27
24	Do ecological factors influence the clinical presentation of amyotrophic lateral sclerosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1017-1019.	1.9	4
25	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
26	A novel splice site FUS mutation in a familial ALS case: effects on protein expression. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-9.	1.7	2
27	Arterial blood gas analysis: base excess and carbonate are predictive of noninvasive ventilation adaptation and survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 33-39.	1.7	8
28	The heterozygous deletion c.1509_1510delAG in exon 14 of FUS causes an aggressive childhood-onset ALS with cognitive impairment. Neurobiology of Aging, 2021, 103, 130.e1-130.e7.	3.1	7
29	Can amyotrophic lateral sclerosis progression really pause? A cohort study using the medical research council scale. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-7.	1.7	1
30	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	9.0	46
31	Developments in the assessment of non-motor disease progression in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2021, 21, 1419-1440.	2.8	10
32	GBA variants influence cognitive status in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, , jnnp-2021-327426.	1.9	3
33	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
34	Regional spreading of symptoms at diagnosis as a prognostic marker in amyotrophic lateral sclerosis: a population-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 291-297.	1.9	18
35	The Characteristics of Cognitive Impairment in ALS Patients Depend on the Lateralization of Motor Damage. Brain Sciences, 2020, 10, 650.	2.3	8
36	TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients. Brain Communications, 2020, 2, fcaa142.	3.3	55

#	Article	IF	Citations
37	Lifetime sport practice and brain metabolism in Amyotrophic Lateral Sclerosis. NeuroImage: Clinical, 2020, 27, 102312.	2.7	7
38	Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 373-379.	1.7	40
39	The role of arterial blood gas analysis (ABG) in amyotrophic lateral sclerosis respiratory monitoring. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 999-1000.	1.9	13
40	Prognostic role of slow vital capacity in amyotrophic lateral sclerosis. Journal of Neurology, 2020, 267, 1615-1621.	3.6	18
41	ALS phenotype is influenced by age, sex, and genetics. Neurology, 2020, 94, e802-e810.	1.1	99
42	Plateaus in amyotrophic lateral sclerosis progression: results from a populationâ€based cohort. European Journal of Neurology, 2020, 27, 1397-1404.	3.3	11
43	A familial amyotrophic lateral sclerosis pedigree discordant for a novel p.Glu46Asp heterozygous OPTN variant and the p.Ala5Val heterozygous SOD1 missense mutation. Journal of Clinical Neuroscience, 2020, 75, 223-225.	1.5	3
44	Acute, Hemorrhagic, Necrotizing Pancreatitis Associated With Riluzole Treatment in a Patient With Amyotrophic Lateral Sclerosis. American Journal of Therapeutics, 2020, Publish Ahead of Print, .	0.9	1
45	Comorbidity of Cervical Spondylogenic Myelopathy and Amyotrophic Lateral Sclerosis: When Electromyography Makes the Difference in Diagnosis. European Neurology, 2020, 83, 626-629.	1.4	1
46	Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study. Journal of Neurology, 2019, 266, 1633-1642.	3.6	25
47	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	5.3	118
48	Validation of the revised classification of cognitive and behavioural impairment in ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 734-739.	1.9	17
49	Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology, 2019, 93, e984-e994.	1.1	115
50	Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 666-673.	1.9	73
51	Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1117-1131.	6.4	18
52	Correlation between Apolipoprotein E genotype and brain metabolism in amyotrophic lateral sclerosis. European Journal of Neurology, 2019, 26, 306-312.	3.3	8
53	Spatial epidemiology of amyotrophic lateral sclerosis in Piedmont and Aosta Valley, Italy: a populationâ€based cluster analysis. European Journal of Neurology, 2018, 25, 756-761.	3.3	9
54	Common polymorphisms of chemokine (Câ€X3â€C motif) receptor 1 gene modify amyotrophic lateral sclerosis outcome: A populationâ€based study. Muscle and Nerve, 2018, 57, 212-216.	2.2	25

#	Article	IF	Citations
55	Longitudinal brain magnetic resonance imaging and realâ€time quaking induced conversion analysis in presymptomatic Creutzfeldtâ€“Jakob disease. European Journal of Neurology, 2018, 25, e127-e128.	3.3	10
56	The multistep hypothesis of ALS revisited. Neurology, 2018, 91, e635-e642.	1.1	146
57	Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis. Brain, 2018, 141, 2272-2279.	7.6	33
58	A novel p.Ser108LeufsTer15 SOD1 mutation leading to the formation of a premature stop codon in an apparently sporadic ALS patient: insights into the underlying pathomechanisms. Neurobiology of Aging, 2018, 72, 189.e11-189.e17.	3.1	3
59	Multicenter validation of [¹⁸F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 570-577.	1.7	19
60	Implementing Motor Unit Number Index (MUNIX) in a large clinical trial: Real world experience from 27 centres. Clinical Neurophysiology, 2018, 129, 1756-1762.	1.5	49
61	Monocytes of patients with amyotrophic lateral sclerosis linked to gene mutations display altered TDPâ€43 subcellular distribution. Neuropathology and Applied Neurobiology, 2017, 43, 133-153.	3.2	23
62	Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 590-597.	1.7	27
63	Secular Trends of Amyotrophic Lateral Sclerosis. JAMA Neurology, 2017, 74, 1097.	9.0	85
64	Acoustic reflex patterns in amyotrophic lateral sclerosis. European Archives of Oto-Rhino-Laryngology, 2017, 274, 679-683.	1.6	5
65	Clinical epidemiology of amyotrophic lateral sclerosis in Liguria, Italy: An update of LIGALS register. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 535-542.	1.7	29
66	Influence of cigarette smoking on ALS outcome: a population-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1229-1233.	1.9	37
67	TBK1 is associated with ALS and ALS-FTD in Sardinian patients. Neurobiology of Aging, 2016, 43, 180.e1-180.e5.	3.1	40
68	A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2061-2071.	6.4	27
69	Metabolic spatial connectivity in amyotrophic lateral sclerosis as revealed by independent component analysis. Human Brain Mapping, 2016, 37, 942-953.	3.6	40
70	The Role ofAPOEin the Occurrence of Frontotemporal Dementia in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2016, 73, 425.	9.0	37
71	¹⁸ F-FDG-PET correlates of cognitive impairment in ALS. Neurology, 2016, 86, 44-49.	1.1	84
72	ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. Neurobiology of Aging, 2015, 36, 2906.e1-2906.e5.	3.1	19

#	Article	IF	Citations
73	Amyotrophic lateral sclerosis onset after prolonged treatment with a VEGF receptors inhibitor. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 129-130.	1.7	5
74	ATXN2 polyQ intermediate repeats are a modifier of ALS survival. Neurology, 2015, 84, 251-258.	1.1	52
75	Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 168-173.	1.9	233
76	A novel p.E121G heterozygous missense mutation of SOD1 in an apparently sporadic ALS case with a 14-year course. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 127-128.	1.7	6
77	Amyotrophic Lateral Sclerosis Outcome Measures and the Role of Albumin and Creatinine. JAMA Neurology, 2014, 71, 1134.	9.0	150
78	The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 844-852.	6.4	103
79	A familial ALS case carrying a novel p.G147CSOD1heterozygous missense mutation with non-executive cognitive impairment: FigureÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1437-1439.	1.9	11
80	Genetic architecture of ALS in Sardinia. Neurobiology of Aging, 2014, 35, 2882.e7-2882.e12.	3.1	60
81	NADPH oxidase (NOX2) activity is a modifier of survival in ALS. Journal of Neurology, 2014, 261, 2178-2183.	3.6	36
82	A de novo nonsense mutation of the FUS gene in an apparently familial amyotrophic lateral sclerosis case. Neurobiology of Aging, 2014, 35, 1513.e7-1513.e11.	3.1	21
83	ALS clinical trials. Neurology, 2011, 77, 1432-1437.	1.1	96